Biogen's experimental Alzheimer's drug diranersen (BIIB080) has shown mixed Phase 2 results, reducing tau protein levels in the brain and spinal fluid but failing its primary dose-response endpoint.
The lowest dose (60 mg) demonstrated the strongest clinical benefit, slowing cognitive decline by about 26% on the CDR-SB scale and 42-50% on other cognitive tests versus placebo, despite not following expected dose-response patterns.
Biogen plans to advance diranersen to Phase 3 trials, marking the first time a tau-targeting therapy has shown both biomarker improvements and cognitive signals, which is generating both excitement and confusion among experts and investors.
The drug's safety profile appears favorable with no amyloid-related imaging abnormalities, but questions remain about optimal dosing strategy and real-world functional benefits.
These results represent a significant milestone in Alzheimer's research as the first evidence that lowering toxic tau protein may translate to clinical benefits, potentially reshaping future treatment approaches.
Sources:
Biogen's tau-targeting Alzheimer's drug sees mixed results
Biogen's Phase 2 Tau Study Marks Encouraging Progress ...
Biogen's Investigational Tau-Targeting Therapy BIIB080 ...
Biogen at aaic 2026: tau drug advances despite mixed trial readout By Investing.com
Biogen advances Alzheimer's drug to late-stage trial despite disappointing data
Biogen to Highlight Breadth of Alzheimer's Disease ...
Exploratory analyses of clinical outcomes from the BIIB080 phase 1b ...
New Clinical Trial Results for Tau-Targeting Diranersen
Biogen's Alzheimer's drug lowers toxic protein, but results ...
[PDF] New Data Presented at the Clinical Trials on Alzheimer's Disease ...
Biogen's experimental Alzheimer's drug targets tau protein
Biogen's new Alzheimer's drug cuts toxic tau protein, but questions over efficacy send stock down 7%
Biogen's Much Anticipated Tau Readout in Alzheimer's Will ...
Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs